These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 18398083)
21. Regulatory perspectives on data monitoring. O'Neill RT Stat Med; 2002 Oct; 21(19):2831-42. PubMed ID: 12325099 [TBL] [Abstract][Full Text] [Related]
22. Application of the Consolidated Standards of Reporting Trials (CONSORT) in the Fracture Care Literature. Bhandari M; Guyatt GH; Lochner H; Sprague S; Tornetta P J Bone Joint Surg Am; 2002 Mar; 84(3):485-9. PubMed ID: 11886922 [No Abstract] [Full Text] [Related]
23. The independent statistician for data monitoring committees. DeMets DL; Fleming TR Stat Med; 2004 May; 23(10):1513-7. PubMed ID: 15122729 [TBL] [Abstract][Full Text] [Related]
25. Editor's note. Braile D Rev Bras Cir Cardiovasc; 2013; 28(3):417. PubMed ID: 24498659 [No Abstract] [Full Text] [Related]
26. Ensuring trial conduct is consistent with trial design: assumption is the enemy of quality. Kelly J; Hounsome B; Lambert G; Murphy C Trials; 2019 Jul; 20(1):416. PubMed ID: 31291974 [TBL] [Abstract][Full Text] [Related]
27. Challenging Issues in Clinical Trial Design: Part 4 of a 4-Part Series on Statistics for Clinical Trials. Pocock SJ; Clayton TC; Stone GW J Am Coll Cardiol; 2015 Dec; 66(25):2886-2898. PubMed ID: 26718676 [TBL] [Abstract][Full Text] [Related]
28. SOP 07a: Monitoring of a trial under CESAR responsibility. Onkologie; 2003 Oct; 26 Suppl 6():38-40. PubMed ID: 23570184 [No Abstract] [Full Text] [Related]
29. Stopping guidelines for an effectiveness trial: what should the protocol specify? Tyson JE; Pedroza C; Wallace D; D'Angio C; Bell EF; Das A Trials; 2016 May; 17(1):240. PubMed ID: 27165260 [TBL] [Abstract][Full Text] [Related]
30. Ethical issues arising when interim data in clinical trials is restricted to independent data monitoring committees. Wells RJ; Gartside PS; McHenry CL IRB; 2000 Jan; 22(1):7-11. PubMed ID: 12546010 [No Abstract] [Full Text] [Related]
31. Playing safe and preserving integrity: making the FDA model work. Wittes J Stat Med; 2004 May; 23(10):1523-5. PubMed ID: 15122731 [TBL] [Abstract][Full Text] [Related]
33. Data safety and monitoring boards for African clinical trials. Lang T; Chilengi R; Noor RA; Ogutu B; Todd JE; Kilama WL; Targett GA Trans R Soc Trop Med Hyg; 2008 Dec; 102(12):1189-94. PubMed ID: 18644610 [TBL] [Abstract][Full Text] [Related]
35. Data safety monitoring boards: a word from a sponsor (NHLBI). Mondoro TH Transfusion; 2009 Aug; 49(8):1537-9. PubMed ID: 19413736 [No Abstract] [Full Text] [Related]
36. Cyclo-oxygenase inhibitors and Alzheimer's: are we well ADAPTed? Pasinetti GM; Pompl PN Lancet Neurol; 2002 Nov; 1(7):403-4. PubMed ID: 12849357 [No Abstract] [Full Text] [Related]
37. Pursuit of truly independent data monitoring committees in research. Marston L; McKenzie DR; Freemantle N BMJ; 2016 May; 353():i2309. PubMed ID: 27172924 [No Abstract] [Full Text] [Related]
38. Phase 0, Phase I in clinical research and the registering of publications. Caramori CA Rev Bras Cir Cardiovasc; 2013; 28(3):414-7. PubMed ID: 24498658 [No Abstract] [Full Text] [Related]
39. Standard versus adaptive monitoring procedures: A commentary. Fleming TR Stat Med; 2006 Oct; 25(19):3305-12; discussion 3313-4, 3326-47. PubMed ID: 16850447 [TBL] [Abstract][Full Text] [Related]